US Bancorp
APGE icon

US Bancorp’s Apogee Therapeutics APGE Stock Holding History

US Bancorp’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2K Sell
190
-558
-75% -$50.3K ﹤0.01% 3105
2026
Q1 		$63K Buy
748
+402
+116% +$29.2K ﹤0.01% 2616
2025
Q4 		$26.1K Sell
346
-54
-14% -$3.4K ﹤0.01% 2975
2025
Q3 		$15.9K Sell
400
-22
-5% -$840 ﹤0.01% 3152
2025
Q2 		$18.3K Buy
422
+373
+761% +$14.2K ﹤0.01% 3201
2025
Q1 		$1.83K Buy
49
+44
+880% +$1.7K ﹤0.01% 3900
2024
Q4 		$227 Buy
+5
New +$255 ﹤0.01% 4072

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

US Bancorp's APGE Position: Q2 2026 in Review

US Bancorp reduced its Apogee Therapeutics (APGE) stake by 75% in Q2 2026, selling an estimated $50.3K and leaving 190 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3105.

US Bancorp first reported a position in APGE in Q4 2024 and has held it in 7 quarters since. The position peaked at $63K in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • US Bancorp held 190 shares of Apogee Therapeutics worth $25.2K as of Q2 2026.
  • US Bancorp sold 558 Apogee Therapeutics shares in Q2 2026, an estimated $50.3K.
  • Apogee Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3105 holding.
  • US Bancorp first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • US Bancorp's Apogee Therapeutics position peaked at $63K in Q1 2026.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.